Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OptiNose Inc.

www.optinose.com

Latest From OptiNose Inc.

Venture Funding Deals: Spin-Outs From Axovant, Inovio & Sosei

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced January and February 2019.

Deals Financing

Deal Watch: Roivant Spins Out Arvelle, Licenses Epilepsy Candidate From SK Biopharma

Already having launched several portfolio companies, Roivant goes a step further by spinning out CNS specialist Arvelle from Axovant. BI and IBM will incorporate blockchain technology in clinical trials, while AbbVie licenses multiple myeloma candidate from TeneoBio.

Business Strategies Commercial

Medicxi Links With Sosei Heptares For Orexin Agonist Vehicles

After spending 12 months looking for promising orexin agonist candidates, asset-centric venture capitalist Medicxi finds answer close to home and commits up to €40M to create two companies underpinned by assets from Heptares Therapeutics.

Neurology Commercial

Finance Watch: Investors Go Nuts For NASH As Madrigal Raises $300m, Galmed Skyrockets

Public Company Edition: Madrigal and Galmed shares more than doubled after reporting what were viewed as positive results in mid-stage NASH studies, with Madrigal going on to raise $300m on the back of the data. Not all is well for publicly traded firms, however, as Advaxis and Flex Pharma reveal layoffs.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
      • Nasal
  • Therapeutic Areas
  • Immune Disorders
  • Neurology, Nervous System
  • Respiratory, Pulmonary
  • Alias(es)
  • OptiNose AS
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • OptiNose Inc.
  • Senior Management
  • Peter K Miller, CEO
    Keith Goldan, CFO
    Per G Djupesland, MD, PhD, CSO
    Ramy A Mahmoud, MD, PhD, Pres. & COO
    John Messina, PharmD, SVP, Clinical Dev.
    Tom Gibbs, Chief Commercial Officer
  • Contact Info
  • OptiNose Inc.
    Phone: (47)(267) 364-3500
    1010 Stony Hill Rd., Ste. 300
    Yardley, PA 19067
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register